You are here

  • Home
  • Archive
  • Volume 12, Issue 1
  • Benefits of early intensive glucose control in preventing diabetes-related complications were sustained for up to 10 yearsCommentary

Article Text

Article menu
Download PDFPDF
Treatment
Benefits of early intensive glucose control in preventing diabetes-related complications were sustained for up to 10 years

https://doi.org/10.1136/ebn.12.1.14

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    R R Holman

    Dr R R Holman, Churchill Hospital, Oxford, UK; rury.holman@dtu.ox.ac.uk

    QUESTION

    In patients with type 2 diabetes, do the benefits of early intensive glucose control in preventing diabetes-related complications continue after the intervention is stopped?

    METHODS

    Design:

    randomised controlled trial (UK Prospective Diabetes Study [UKPDS]).

    Allocation:

    {concealed}.*

    Blinding:

    blinded (outcome adjudication committee).

    Follow-up period:

    median 9 years after the end of the trial, 17 years total.

    Setting:

    23 centres in the UK.

    Patients:

    4209 patients 25–65 years of age {mean age 53 y, 60% men}* who had newly diagnosed type 2 diabetes and fasting plasma glucose concentrations >6.0 mmol/l (108 mg/dl) and <15.0 mmol/l (270 mg/dl) after 3 months of dietary therapy. Exclusion criteria included ketonuria, elevated serum creatinine, recent myocardial infarction, angina, …

    View Full Text

    Footnotes

    • Source of funding: UK Medical Research Council; UK Department of Health; Diabetes UK; British Heart Foundation; UK National Institute for Health; Bristol-Myers Squibb; GlaxoSmithKline; Mereck Serono; Norvartis; Novo Nordisk; Pfizer.